{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,7]],"date-time":"2026-09-07T10:24:18Z","timestamp":1788776658149,"version":"build-2803163510"},"reference-count":44,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2025,5,1]],"date-time":"2025-05-01T00:00:00Z","timestamp":1746057600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,5,1]],"date-time":"2025-05-01T00:00:00Z","timestamp":1746057600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,5,1]],"date-time":"2025-05-01T00:00:00Z","timestamp":1746057600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2025,5,1]],"date-time":"2025-05-01T00:00:00Z","timestamp":1746057600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2025,5,1]],"date-time":"2025-05-01T00:00:00Z","timestamp":1746057600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2025,5,1]],"date-time":"2025-05-01T00:00:00Z","timestamp":1746057600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2025,5,1]],"date-time":"2025-05-01T00:00:00Z","timestamp":1746057600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/501100003725","name":"National Research Foundation of Korea","doi-asserted-by":"publisher","award":["RS-2022-NR073094"],"award-info":[{"award-number":["RS-2022-NR073094"]}],"id":[{"id":"10.13039\/501100003725","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["International Journal of Biological Macromolecules"],"published-print":{"date-parts":[[2025,5]]},"DOI":"10.1016\/j.ijbiomac.2025.142167","type":"journal-article","created":{"date-parts":[[2025,3,19]],"date-time":"2025-03-19T21:40:58Z","timestamp":1742420458000},"page":"142167","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":3,"special_numbering":"P4","title":["EGFR Affibody and PEG functionalized protein nanoparticles: Sustaining targeting and macrophage evasion"],"prefix":"10.1016","volume":"307","author":[{"given":"Seonhye","family":"Jang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Heejin","family":"Jun","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Soomin","family":"Eom","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sheng","family":"Zhao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Niren","family":"Murthy","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sebyung","family":"Kang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hansol","family":"Kim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"1","key":"10.1016\/j.ijbiomac.2025.142167_bb0005","doi-asserted-by":"crossref","first-page":"2","DOI":"10.1016\/j.gene.2005.10.018","article-title":"Epidermal growth factor receptor (EGFR) signaling in cancer","volume":"366","author":"Normanno","year":"2006","journal-title":"Gene"},{"issue":"11","key":"10.1016\/j.ijbiomac.2025.142167_bb0010","doi-asserted-by":"crossref","DOI":"10.3390\/cancers13112748","article-title":"EGFR in Cancer: signaling mechanisms, drugs, and acquired resistance","volume":"13","author":"Uribe","year":"2021","journal-title":"Cancers (Basel)"},{"issue":"1","key":"10.1016\/j.ijbiomac.2025.142167_bb0015","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1002\/1878-0261.12155","article-title":"Emerging functions of the EGFR in cancer","volume":"12","author":"Sigismund","year":"2018","journal-title":"Mol. Oncol."},{"key":"10.1016\/j.ijbiomac.2025.142167_bb0020","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1016\/S0959-8049(01)00230-1","article-title":"The EGFR family and its ligands in human cancer: signalling mechanisms and therapeutic opportunities","volume":"37","author":"Yarden","year":"2001","journal-title":"Eur. J. Cancer"},{"issue":"2","key":"10.1016\/j.ijbiomac.2025.142167_bb0025","doi-asserted-by":"crossref","first-page":"301","DOI":"10.1111\/j.1742-4658.2009.07448.x","article-title":"Epidermal growth factor receptor in relation to tumor development: EGFR gene and cancer","volume":"277","author":"Mitsudomi","year":"2010","journal-title":"FEBS J."},{"issue":"21","key":"10.1016\/j.ijbiomac.2025.142167_bb0030","doi-asserted-by":"crossref","first-page":"7060","DOI":"10.1158\/1078-0432.CCR-08-1455","article-title":"Effects of erlotinib in EGFR mutated non-small cell lung cancers with resistance to gefitinib","volume":"14","author":"Costa","year":"2008","journal-title":"Clin. Cancer Res."},{"issue":"6","key":"10.1016\/j.ijbiomac.2025.142167_bb0035","doi-asserted-by":"crossref","DOI":"10.1093\/jnci\/djw279","article-title":"Gefitinib or Erlotinib vs chemotherapy for EGFR mutation-positive lung Cancer: individual patient data Meta-analysis of overall survival","volume":"109","author":"Lee","year":"2017","journal-title":"JNCI J. Natl. Cancer Inst."},{"issue":"1","key":"10.1016\/j.ijbiomac.2025.142167_bb0040","doi-asserted-by":"crossref","first-page":"88","DOI":"10.1186\/s12859-018-2093-6","article-title":"Prediction of sensitivity to gefitinib\/erlotinib for EGFR mutations in NSCLC based on structural interaction fingerprints and multilinear principal component analysis","volume":"19","author":"Zou","year":"2018","journal-title":"BMC Bioinformatics."},{"issue":"1","key":"10.1016\/j.ijbiomac.2025.142167_bb0045","doi-asserted-by":"crossref","first-page":"328","DOI":"10.1186\/s13046-021-02130-2","article-title":"Resistance to anti-EGFR therapies in metastatic colorectal cancer: underlying mechanisms and reversal strategies","volume":"40","author":"Zhou","year":"2021","journal-title":"J. Exp. Clin. Cancer Res."},{"key":"10.1016\/j.ijbiomac.2025.142167_bb0050","doi-asserted-by":"crossref","first-page":"16","DOI":"10.1016\/S0959-8049(01)00233-7","article-title":"The EGFR as a target for anticancer therapy\u2014focus on cetuximab","volume":"37","author":"Baselga","year":"2001","journal-title":"Eur. J. Cancer"},{"issue":"6","key":"10.1016\/j.ijbiomac.2025.142167_bb0055","doi-asserted-by":"crossref","DOI":"10.3390\/ijms24065994","article-title":"NANOBODIES\u00ae: a review of diagnostic and therapeutic applications","volume":"24","author":"Jin","year":"2023","journal-title":"Int. J. Mol. Sci."},{"key":"10.1016\/j.ijbiomac.2025.142167_bb0060","doi-asserted-by":"crossref","DOI":"10.1155\/2012\/980250","article-title":"scFv antibody: principles and clinical application","volume":"2012","author":"Ahmad","year":"2012","journal-title":"Clin. Dev. Immunol."},{"issue":"3","key":"10.1016\/j.ijbiomac.2025.142167_bb0065","doi-asserted-by":"crossref","DOI":"10.1038\/emm.2017.35","article-title":"Affibody molecules as engineered protein drugs","volume":"49","author":"Frejd","year":"2017","journal-title":"Exp. Mol. Med."},{"issue":"10","key":"10.1016\/j.ijbiomac.2025.142167_bb0070","doi-asserted-by":"crossref","first-page":"635","DOI":"10.1093\/protein\/gzt038","article-title":"High-affinity binding to staphylococcal protein a by an engineered dimeric Affibody molecule","volume":"26","author":"Lindborg","year":"2013","journal-title":"Protein Eng. Des. Sel."},{"issue":"1","key":"10.1016\/j.ijbiomac.2025.142167_bb0075","doi-asserted-by":"crossref","first-page":"159","DOI":"10.1186\/s12951-021-00896-3","article-title":"Protein nanoparticles in drug delivery: animal protein, plant proteins and protein cages, albumin nanoparticles","volume":"19","author":"Kianfar","year":"2021","journal-title":"J. Nanobiotechnol."},{"issue":"7","key":"10.1016\/j.ijbiomac.2025.142167_bb0080","doi-asserted-by":"crossref","DOI":"10.3390\/pharmaceutics12070604","article-title":"Protein-based nanoparticles as drug delivery systems","volume":"12","author":"Hong","year":"2020","journal-title":"Pharmaceutics"},{"key":"10.1016\/j.ijbiomac.2025.142167_bb0085","doi-asserted-by":"crossref","DOI":"10.1016\/j.ijpharm.2020.119289","article-title":"Protein-based nanoparticles for drug delivery purposes","volume":"581","author":"Mart\u00ednez-L\u00f3pez","year":"2020","journal-title":"Int. J. Pharm."},{"issue":"5","key":"10.1016\/j.ijbiomac.2025.142167_bb0090","doi-asserted-by":"crossref","first-page":"1099","DOI":"10.1006\/jmbi.2000.4435","article-title":"X-ray structure analysis and crystallographic refinement of lumazine synthase from the hyperthermophile Aquifex aeolicus at 1.6 \u00c5 resolution: determinants of thermostability revealed from structural comparisons1 1Edited by R. Huber","volume":"306","author":"Zhang","year":"2001","journal-title":"Journal of Molecular Biology"},{"issue":"4","key":"10.1016\/j.ijbiomac.2025.142167_bb0095","doi-asserted-by":"crossref","first-page":"487","DOI":"10.1016\/j.nantod.2015.06.006","article-title":"Nanoparticle uptake: the phagocyte problem","volume":"10","author":"Gustafson","year":"2015","journal-title":"Nano Today"},{"issue":"1","key":"10.1016\/j.ijbiomac.2025.142167_bb0100","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1016\/j.coi.2005.11.008","article-title":"The mononuclear phagocyte system","volume":"18","author":"Hume","year":"2006","journal-title":"Curr. Opin. Immunol."},{"issue":"1","key":"10.1016\/j.ijbiomac.2025.142167_bb0105","doi-asserted-by":"crossref","first-page":"93","DOI":"10.1016\/j.ijpharm.2005.10.010","article-title":"Opsonization, biodistribution, and pharmacokinetics of polymeric nanoparticles","volume":"307","author":"Owens","year":"2006","journal-title":"Int. J. Pharm."},{"key":"10.1016\/j.ijbiomac.2025.142167_bb0110","doi-asserted-by":"crossref","first-page":"28","DOI":"10.1016\/j.addr.2015.09.012","article-title":"PEGylation as a strategy for improving nanoparticle-based drug and gene delivery","volume":"99","author":"Suk","year":"2016","journal-title":"Adv. Drug Deliv. Rev."},{"key":"10.1016\/j.ijbiomac.2025.142167_bb0115","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1016\/j.jconrel.2022.09.002","article-title":"Stealth nanoparticles in oncology: facing the PEG dilemma","volume":"351","author":"Zalba","year":"2022","journal-title":"J. Control. Release"},{"issue":"6","key":"10.1016\/j.ijbiomac.2025.142167_bb0120","doi-asserted-by":"crossref","first-page":"1432","DOI":"10.1039\/D2LC00799A","article-title":"Nanoparticle protein corona: from structure and function to therapeutic targeting","volume":"23","author":"Bashiri","year":"2023","journal-title":"Lab Chip"},{"issue":"39","key":"10.1016\/j.ijbiomac.2025.142167_bb0125","doi-asserted-by":"crossref","first-page":"10764","DOI":"10.1021\/acs.langmuir.5b02158","article-title":"Stealth effect of biomolecular Corona on nanoparticle uptake by immune cells","volume":"31","author":"Caracciolo","year":"2015","journal-title":"Langmuir"},{"issue":"7","key":"10.1016\/j.ijbiomac.2025.142167_bb0130","doi-asserted-by":"crossref","first-page":"2050","DOI":"10.1073\/pnas.0608582104","article-title":"Understanding the nanoparticle\u2013protein corona using methods to quantify exchange rates and affinities of proteins for nanoparticles","volume":"104","author":"Cedervall","year":"2007","journal-title":"Proc. Natl. Acad. Sci."},{"issue":"4","key":"10.1016\/j.ijbiomac.2025.142167_bb0135","doi-asserted-by":"crossref","first-page":"387","DOI":"10.1038\/nnano.2016.269","article-title":"Complement proteins bind to nanoparticle protein corona and undergo dynamic exchange in vivo","volume":"12","author":"Chen","year":"2017","journal-title":"Nat. Nanotechnol."},{"key":"10.1016\/j.ijbiomac.2025.142167_bb0140","doi-asserted-by":"crossref","DOI":"10.1016\/j.copbio.2023.103010","article-title":"Interactions between nanoparticle corona proteins and the immune system","volume":"84","author":"Tran","year":"2023","journal-title":"Curr. Opin. Biotechnol."},{"issue":"11","key":"10.1016\/j.ijbiomac.2025.142167_bb0145","doi-asserted-by":"crossref","first-page":"788","DOI":"10.1038\/nri3087","article-title":"Studying the mononuclear phagocyte system in the molecular age","volume":"11","author":"Chow","year":"2011","journal-title":"Nat. Rev. Immunol."},{"key":"10.1016\/j.ijbiomac.2025.142167_bb0150","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1016\/j.jconrel.2017.01.024","article-title":"Mononuclear phagocytes as a target, not a barrier, for drug delivery","volume":"259","author":"Yong","year":"2017","journal-title":"J. Control. Release"},{"issue":"3","key":"10.1016\/j.ijbiomac.2025.142167_bb0155","doi-asserted-by":"crossref","first-page":"301","DOI":"10.1016\/S0927-7765(99)00156-3","article-title":"\u2018Stealth\u2019 corona-core nanoparticles surface modified by polyethylene glycol (PEG): influences of the corona (PEG chain length and surface density) and of the core composition on phagocytic uptake and plasma protein adsorption","volume":"18","author":"Gref","year":"2000","journal-title":"Colloids Surf. B Biointerfaces"},{"issue":"3","key":"10.1016\/j.ijbiomac.2025.142167_bb0160","doi-asserted-by":"crossref","first-page":"214","DOI":"10.1038\/nrd1033","article-title":"Effect of pegylation on pharmaceuticals","volume":"2","author":"Harris","year":"2003","journal-title":"Nat. Rev. Drug Discov."},{"issue":"22","key":"10.1016\/j.ijbiomac.2025.142167_bb0165","doi-asserted-by":"crossref","DOI":"10.3390\/app9224789","article-title":"Quantification of the PEGylated gold nanoparticles protein Corona. Influence on nanoparticle size and surface chemistry","volume":"9","author":"Nicoar\u0103","year":"2019","journal-title":"Appl. Sci."},{"key":"10.1016\/j.ijbiomac.2025.142167_bb0170","doi-asserted-by":"crossref","first-page":"70","DOI":"10.1016\/j.ejpb.2019.05.006","article-title":"Effect of nanoparticle size and PEGylation on the protein corona of PLGA nanoparticles","volume":"141","author":"Partikel","year":"2019","journal-title":"Eur. J. Pharm. Biopharm."},{"issue":"2","key":"10.1016\/j.ijbiomac.2025.142167_bb0175","doi-asserted-by":"crossref","first-page":"1","DOI":"10.14302\/issn.2835-513X.ijl-20-3457","article-title":"Understanding the stealth properties of PEGylated lipids: a mini-review","volume":"1","author":"Poornima","year":"2020","journal-title":"International Journal of Lipids."},{"issue":"5","key":"10.1016\/j.ijbiomac.2025.142167_bb0180","doi-asserted-by":"crossref","first-page":"315","DOI":"10.2165\/00063030-200822050-00004","article-title":"The impact of PEGylation on biological therapies","volume":"22","author":"Veronese","year":"2008","journal-title":"BioDrugs"},{"issue":"21","key":"10.1016\/j.ijbiomac.2025.142167_bb0185","doi-asserted-by":"crossref","first-page":"1451","DOI":"10.1016\/S1359-6446(05)03575-0","article-title":"PEGylation, successful approach to drug delivery","volume":"10","author":"Veronese","year":"2005","journal-title":"Drug Discov. Today"},{"issue":"4","key":"10.1016\/j.ijbiomac.2025.142167_bb0190","doi-asserted-by":"crossref","first-page":"20230027","DOI":"10.1002\/EXP.20230027","article-title":"Stimuli-responsive linkers and their application in molecular imaging","volume":"4","author":"Wang","year":"2024","journal-title":"Exploration"},{"issue":"33","key":"10.1016\/j.ijbiomac.2025.142167_bb0195","doi-asserted-by":"crossref","first-page":"8973","DOI":"10.1039\/D0SC00929F","article-title":"A traceless linker for aliphatic amines that rapidly and quantitatively fragments after reduction","volume":"11","author":"He","year":"2020","journal-title":"Chem. Sci."},{"issue":"12","key":"10.1016\/j.ijbiomac.2025.142167_bb0200","doi-asserted-by":"crossref","DOI":"10.1073\/pnas.1115485109","article-title":"Peptide tag forming a rapid covalent bond to a protein, through engineering a bacterial adhesin","volume":"109","author":"Zakeri","year":"2012","journal-title":"Proc. Natl. Acad. Sci."},{"issue":"5153","key":"10.1016\/j.ijbiomac.2025.142167_bb0205","doi-asserted-by":"crossref","first-page":"1600","DOI":"10.1126\/science.8128245","article-title":"Biodegradable long-circulating polymeric Nanospheres","volume":"263","author":"Gref","year":"1994","journal-title":"Science"},{"issue":"7","key":"10.1016\/j.ijbiomac.2025.142167_bb0210","doi-asserted-by":"crossref","first-page":"3865","DOI":"10.1007\/s00289-019-02924-7","article-title":"Nanoparticle opsonization: forces involved and protection by long chain polymers","volume":"77","author":"Wani","year":"2020","journal-title":"Polym. Bull."},{"key":"10.1016\/j.ijbiomac.2025.142167_bb0215","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2020.567365","article-title":"Opsonins and Dysopsonins of nanoparticles: facts, concepts, and methodological guidelines","volume":"11","author":"Papini","year":"2020","journal-title":"Front. Immunol."},{"issue":"9","key":"10.1016\/j.ijbiomac.2025.142167_bb0220","doi-asserted-by":"crossref","first-page":"941","DOI":"10.1038\/nbt.3330","article-title":"Principles of nanoparticle design for overcoming biological barriers to drug delivery","volume":"33","author":"Blanco","year":"2015","journal-title":"Nat. Biotechnol."}],"container-title":["International Journal of Biological Macromolecules"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0141813025027199?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0141813025027199?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,7,1]],"date-time":"2026-07-01T03:30:41Z","timestamp":1782876641000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0141813025027199"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,5]]},"references-count":44,"alternative-id":["S0141813025027199"],"URL":"https:\/\/doi.org\/10.1016\/j.ijbiomac.2025.142167","relation":{},"ISSN":["0141-8130"],"issn-type":[{"value":"0141-8130","type":"print"}],"subject":[],"published":{"date-parts":[[2025,5]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"EGFR Affibody and PEG functionalized protein nanoparticles: Sustaining targeting and macrophage evasion","name":"articletitle","label":"Article Title"},{"value":"International Journal of Biological Macromolecules","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ijbiomac.2025.142167","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 Elsevier B.V. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"142167"}}